Reversal Strategies for NOACs: State of Development, Possible Clinical Applications and Future Perspectives

Drug Safety

Volumn 39, Issue 1, 2016, Pages 5-13

  Husted, Steen ^a   Verheugt, Freek W A ^b   Comuth, Willemijn J ^a  

^a REGIONAL HOSPITAL WEST JUTLAND   (Denmark)

^b ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANDEXANET ALFA; ANTIDOTE; APIXABAN; BLOOD CLOTTING FACTOR; CIRAPARANTAG; DABIGATRAN; EDOXABAN; IDARUCIZUMAB; RIVAROXABAN; ANTICOAGULANT AGENT;

ANTICOAGULATION; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; BLOOD CLOTTING; DRUG BLOOD LEVEL; DRUG EXCRETION; DRUG INDICATION; DRUG MECHANISM; HUMAN; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RISK ASSESSMENT; VENOUS THROMBOEMBOLISM; ANIMAL; CHEMICALLY INDUCED; COMPLICATION; HEMORRHAGE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; ANTIDOTES; ATRIAL FIBRILLATION; HEMORRHAGE; HUMANS; VENOUS THROMBOEMBOLISM;

EID: 84954405088     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-015-0357-x     Document Type: Article

References (57)

1. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–62.
2. Blaich C, Muller C, Michels G, Wiesen MH. Multi-analyte analysis of non-vitamin K antagonist oral anticoagulants in human plasma using tandem mass spectrometry. Clin Chem Lab Med. 2015. http://www.degruyter.com/view/j/cclm.ahead-of-print/cclm-2014-1108/cclm-2014-1108.xml.
3. Douxfils J, Mani H, Minet V, Devalet B, Chatelain B, Dogne JM, et al. Non-VKA oral anticoagulants: accurate measurement of plasma drug concentrations. Biomed Res Int. 2015;2015:345138.
4. Ruff CT, Giugliano RP, Braunwald E, Morrow DA, Murphy SA, Kuder JF, et al. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet. 2015;385(9984):2288–95.
5. Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol. 2014;63(4):321–8.
6. Eikelboom JW, Connolly SJ, Brueckmann M, Granger CB, Kappetein AP, Mack MJ, et al. Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med. 2013;369(13):1206–14.
7. Samama MM, Meddahi S, Samama CM. Pharmacology and laboratory testing of the oral Xa inhibitors. Clin Lab Med. 2014;34(3):503–17.
8. Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol. 2014;64(11):1128–39.
9. Samama MM, Guinet C. Laboratory assessment of new anticoagulants. Clin Chem Lab Med. 2011;49(5):761–72.
10. Garcia D, Barrett YC, Ramacciotti E, Weitz JI. Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost. 2013;11(2):245–52.
11. Cohen D. Dabigatran: how the drug company withheld important analyses. BMJ. 2014;23(349):g4670.
12. Hyphen Biomed. Application sheet for dabigatran with hemoclot thrombin inhibitors v3. Available at: http://www.aniara.com/pdf/ADA-ACK002KLCS2000i-2100i.pdf. Accessed July 2015.
13. Faaborg L, Comuth WJ, Bloch-Münster AM, Henriksen LØ, Husted S. Handling of the hemoclot thrombin inhibitor assay reagents on Sysmex CS-2100i when monitoring dabigatran in acute clinical situations. Poster, XXV International Society on Thrombosis and Haemostasis Congress, Toronto, Canada 2015, Abstract (June). http://www.postersessiononline.eu/pr/aula_poster.asp?congreso=740245997. Accessed 19 Oct 2015.
14. Schmitz EM, Boonen K, van den Heuvel DJ, van Dongen JL, Schellings MW, Emmen JM, et al. Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography–tandem mass spectrometry (UPLC–MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. J Thromb Haemost. 2014;12(10):1636–46.
15. Antovic JP, Skeppholm M, Eintrei J, Boija EE, Soderblom L, Norberg EM, et al. Evaluation of coagulation assays versus LC–MS/MS for determinations of dabigatran concentrations in plasma. Eur J Clin Pharmacol. 2013;69(11):1875–81.
16. Hawes EM, Deal AM, Funk-Adcock D, Gosselin R, Jeanneret C, Cook AM, et al. Performance of coagulation tests in patients on therapeutic doses of dabigatran: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. J Thromb Haemost. 2013;11(8):1493–502.
17. Bates SM, Weitz JI. Coagulation assays. Circulation. 2005;112(4):e53–60.
18. Lange U, Nowak G, Bucha E. Ecarin chromogenic assay—a new method for quantitative determination of direct thrombin inhibitors like hirudin. Pathophysiol Haemost Thromb. 2003–2004;33(4):184–191.
19. Douxfils J, Chatelain B, Hjemdahl P, Devalet B, Sennesael AL, Wallemacq P, et al. Does the Russell Viper Venom time test provide a rapid estimation of the intensity of oral anticoagulation? A cohort study. Thromb Res. 2015;135(5):852–60.
20. Kluft C, Burggraaf J. Introduction to haemostasis from a pharmacodynamic perspective. Br J Clin Pharmacol. 2011;72(4):538–46.
21. Dinkelaar J, Patiwael S, Harenberg J, Leyte A, Brinkman HJ. Global coagulation tests: their applicability for measuring direct factor Xa- and thrombin inhibition and reversal of anticoagulation by prothrombin complex concentrate. Clin Chem Lab Med. 2014;52(11):1615–23.
22. Gatt A, van Veen JJ, Woolley AM, Kitchen S, Cooper P, Makris M. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro. Thromb Haemost. 2008;100(2):350–5.
23. Lance MD. A general review of major global coagulation assays: thrombelastography, thrombin generation test and clot waveform analysis. Thromb J 2015;13:1. doi:10.1186/1477-9560-13-1.
24. Beyer-Westendorf J, Forster K, Pannach S, Ebertz F, Gelbricht V, Thieme C, et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood. 2014;124(6):955–62.
25. Beyer-Westendorf J, Ebertz F, Forster K, Gelbricht V, Michalski F, Kohler C, et al. Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost. 2015;113(6):1247–57.
26. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013;15(5):625–51.
27. Pollack CV Jr, Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med. 2015;373(6):511–20.
28. Verheugt FW, Granger CB. Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. Lancet. 2015;386(9990):303–10.
29. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation. 2011;124(14):1573–9.
30. Levi M, Moore KT, Castillejos CF, Kubitza D, Berkowitz SD, Goldhaber SZ, et al. Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers. J Thromb Haemost. 2014;12(9):1428–36.
31. Martin AC, Le Bonniec B, Fischer AM, Marchand-Leroux C, Gaussem P, Samama CM, et al. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. Int J Cardiol. 2013;168(4):4228–33.
32. Zhou W, Schwarting S, Illanes S, Liesz A, Middelhoff M, Zorn M, et al. Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran. Stroke. 2011;42(12):3594–9.
33. Godier A, Miclot A, Le Bonniec B, Durand M, Fischer AM, Emmerich J, et al. Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model. Anesthesiology. 2012;116(1):94–102.
34. Schiele F, van Ryn J, Canada K, Newsome C, Sepulveda E, Park J, et al. A specific antidote for dabigatran: functional and structural characterization. Blood. 2013;121(18):3554–62.
35. Glund S, Stangier J, Schmohl M. Idarucizumab, a specific antidote for dabigatran: immediate, complete and sustained reversal of dabigatran induced anticoagulation in elderly and renally impaired subjects. Blood. 2014;124(344). http://www.bloodjournal.org/content/124/21/344. Accessed 19 Oct 2015.
36. Glund S, Moschetti V, Norris S, Stangier J, Schmohl M, van Ryn J, et al. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost. 2015;113(5):943–51.
37. Glund S, Stangier J, Schmohl M, Gansser D, Norris S, van Ryn J, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet. 2015;386(9994):680–90.
38. Grottke O, Honickel M, van Ryn J, Ten Cate H, Rossaint R, Spronk HM. Idarucizumab, a specific dabigatran reversal agent, reduces blood loss in a porcine model of trauma with dabigatran anticoagulation. J Am Coll Cardiol. 2015;66(13):1518–9.
39. Lu G, DeGuzman FR, Hollenbach SJ, Karbarz MJ, Abe K, Lee G, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19(4):446–51.
40. Hollenbach S, Tan S, Deguzman F, Malinowski J, Hutchaleelaha A, Inagaki M, et al. PRT064445 reverses rivaroxaban induced anticoagulation in a rabbit liver laceration “treatment” model. Eur Heart J. 2013;241. http://eurheartj.oxfordjournals.org/content/34/suppl_1/P241. Accessed 19 Oct 2015.
41. Lu G, Deguzman F, Hollenbach S, Luan P, Abe K, Siu G, et al. Reversal of low molecular weight heparin and fondaparinux by a recombinant antidote (r-Antidote, PRT064445). Abstract 12420. Circulation. 2010;122. http://circ.ahajournals.org/cgi/content/meeting_abstract/122/21_MeetingAbstracts/A12420. Accessed 19 Oct 2015.
42. Hollenbach S, Lu G, Deguzman F, Curnutte J, Conley P, Sinha U. Bolus administration of PRT064445, a recombinant factor Xa inhibitor antidote, reverses blood loss and PD markers in a rat model following enoxaparin-induced anticoagulation. Abstract P1857. Eur Heart J. 2012;33 (abstract supplement):309. http://www.postersessiononline.eu/pr/aula_poster.asp?congreso=740245997&direccion_posters=Seleccion&pagina_posters=5&ordenacion=n_poster&cod_congreso_integracion=&pst_clave=&buscar=&swAcceso=&swAccesoAdmin=&cod_congreso_aula_rel=&busqueda_rapida=&tipo=autor&texto=&texto2=&grupo2_aula=&grupo=&texto_ident=. Accessed 19 Oct 2015.
43. Crowther M, Levy G, Lu G. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of edoxaban-induced anticoagulation in healthy subjects by andexanet Alfa (PRT064445), a universal antidote for factor Xa (FXa) inhibitors. Blood. 2014;124. http://www.bloodjournal.org/content/124/21/4269?sso-checked=true. Accessed 19 Oct 2015 (abstract).
44. Crowther M, Lu G, Conley P. Sustained reversal of apixaban anticoagulation with andexanet alfa using a bolus plus infusion regimen in a phase 2 placebo controlled trial. Eur.Heart J. 2014;35(137). http://spo.escardio.org/SessionDetails.aspx?eevtid=69&sessId=14101&subSessId=3562#.VgqhNPntmko. Accessed 19 Oct 2015 (abstract).
45. Crowther M, Mathur A, Kitt M. A phase 2 randomized, double-blind, placebo-controlled trial demonstrating reversal of rivaroxaban-induced anticoagulation in healthy subjects by andexanet alfa (PRT064445), an antidote for FXa inhibitors. Blood. 2013;122(A 3636). http://www.bloodjournal.org/content/122/21/3636. Accessed 19 Oct 2015 (abstract).
46. Crowther M, Levy G, Lu G. ANNEXA (TM)–R: A phase 3 randomized, double-blind, placebo-controlled trial, demonstrating reversal of apixaban-induced anticoagulation in older subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (FXa) inhibitors. Circulation. 2014;130:2116–7. Accessed 19 Oct 2015 (abstract).
47. Gold A, Crowther M, Levy G. ANNEXA (TM)–R: A phase 3 randomized, double-blind, placebo-controlled trial, demonstrating reversal of rivaroxaban-induced anticoagulation in older subjects by andexanet alfa (PRT064445), a universal antidote for factor Xa (FXa) inhibitors. J Am Coll Cardiol. 2015. http://content.onlinejacc.org/article.aspx?articleid=2196748(abstract).
48. Laulicht B, Bakhru S, Lee C. Small molecule antidote for anticoagulants. Circulation. 2012;126(A11395). http://circ.ahajournals.org/cgi/content/meeting_abstract/126/21_MeetingAbstracts/A11395(abstract).
49. Laulicht B, Bakhru S, Jiang X. Antidote for new oral anticoagulants: mechanism of action and binding specificity of PER977. J Thromb Haemost JTH. 2013;11:75. http://perosphere.com/content/media/documents/AntidoteforNewOralAnticoagulants-MechanismofActionandBindingSpecificityofPER977.pdf(abstract).
50. Bakhru S, Laulicht B, Jiang X. PER977: a synthetic small molecule which reverses over-dosage and bleeding by new oral anticoagulants. Circulation. 2013;128. http://circ.ahajournals.org/cgi/content/meeting_abstract/128/22_MeetingAbstracts/A18809(abstract).
51. Ansell J, Laulicht B, Bakhru S. Aripazine reverses unfractionated and low molecular weight heparins, fondaparinux and new Xa and IIa oral anticoagulants: report of Phase I/II clinical trial with edoxaban. Eur Heart J. 2014;35:854–5.
52. Ansell JE, Bakhru SH, Laulicht BE, Steiner SS, Grosso M, Brown K, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med. 2014;371(22):2141–2.
53. Mueck W, Borris LC, Dahl OE, Haas S, Huisman MV, Kakkar AK, et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost. 2008;100(3):453–61.
54. Mueck W, Lensing AW, Agnelli G, Decousus H, Prandoni P, Misselwitz F. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet. 2011;50(10):675–86.
55. Skeppholm M, Al-Aieshy F, Berndtsson M, Al-Khalili F, Ronquist-Nii Y, Soderblom L, et al. Clinical evaluation of laboratory methods to monitor apixaban treatment in patients with atrial fibrillation. Thromb Res. 2015;136(1):148–53.
56. Bristol-Myers Squibb. Summary of product characteristics. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002148/WC500107728.pdf. Accessed 9 Jul 2015.
57. Weitz JI, Connolly SJ, Patel I, Salazar D, Rohatagi S, Mendell J, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104(3):633–41.